Virtu Financial LLC Takes Position in Novavax, Inc. (NASDAQ:NVAX)

Virtu Financial LLC bought a new position in Novavax, Inc. (NASDAQ:NVAX) in the fourth quarter, Holdings Channel reports. The firm bought 29,830 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

Other large investors also recently bought and sold shares of the company. Spire Wealth Management acquired a new stake in shares of Novavax during the fourth quarter worth $29,000. KBC Group NV raised its stake in Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. acquired a new stake in Novavax during the 4th quarter worth about $86,000. AlphaQuest LLC grew its stake in Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 7,940 shares during the last quarter. Finally, Xponance Inc. acquired a new position in shares of Novavax in the fourth quarter valued at about $95,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Activity

In other Novavax news, Director James F. Young sold 5,400 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.00% of the company’s stock.

Novavax Stock Performance

NVAX stock opened at $7.00 on Friday. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86. The firm’s fifty day moving average is $8.13 and its 200 day moving average is $9.37. The firm has a market cap of $1.13 billion, a PE ratio of -3.10, a P/E/G ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) EPS. Research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on NVAX shares. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, TD Cowen raised shares of Novavax to a “hold” rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.